A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures (Q47926989)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 October 2015

Language	Label	Description	Also known as
English	A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures	scientific article published on 16 October 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

0 references

0 references

Christian Brandt

7

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Michael R Sperling

3

object named as

Michael R Sperling

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

author name string

Pavel Klein

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Jimmy Schiemann

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

John Whitesides

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Wei Liang

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Tracy Stalvey

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Patrick Kwan

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

publication date

16 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

56

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

12

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

1890-1898

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Estimation of the burden of active and life-time epilepsy: a meta-analytic approach

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Patterns of treatment response in newly diagnosed epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Newer drugs for focal epilepsy in adults

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

SV2 modulates the size of the readily releasable pool of secretory vesicles

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13212

21 January 2018

Identifiers

10.1111/EPI.13212

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/26471380

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47926989&oldid=2175972332"